Durham biotech startup Aceragen moves to liquidate assets
Unable to secure funding to support its operations, Durham biotech Aceragen plans to liquidate its assets.
Read More
aceragen
Durham biotech startup backed by NovaQuest merges with public pharma firm
Aceragen, a Triangle-based biopharmaceutical company launched last year with a focus on rare illnesses and hopes to be the first to find a treatment for Farber disease, is merging with a publicly held pharmaceutical firm in an all-stock deal.
Read More
Startup Spotlight: Two Raleigh biopharma firms join forces in search for potential therapies
Raleigh-based Aceragen, a biopharmaceutical company developing therapeutics for rare and orphan diseases, has acquired Arrevus, another Raleigh company with a similar focus.
Read More
Biopharma deal: NovaQuest-backed Aceragen buys Arrevus
Two Triangle biopharmaceutical companies will now operate as one, as Aceragen buys Arrevus.
Read More
Startup Spotlight: New biopharma targets rare diseases with $35M in backing from NovaQuest
A new North Carolina-based biopharmaceutical company with a focus on rare illnesses hopes to be the first to find a treatment for Farber disease. And Raleigh-based NoaQuest is providing $35 million in backing.
Read More
